ReviewDrugs2020
Dolutegravir/Lamivudine Single-Tablet Regimen: A Review in HIV-1 Infection.
Review in Drugs, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 37 citations in OpenAlex.
- Trial
- Renal outcomes with dolutegravir plus lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide in ART-naive adults with HIV.AIDS (London, England) · 2026Article
- The Epidemiology of HIV-1 Resistance to Two-Drug Regimens in Multicenter Cohort From Poland-A Cross-Sectional Study.Health science reports · 2026Article
- The Role of Protease Inhibitors in HIV Treatment: Who Still Needs Them in 2025?Infectious diseases and therapy · 2025Article
- Safe Switch to an Oral Two-Drug Regimen Based on Dolutegravir in People With Vertically Acquired HIV-1: An Observational Multicenter Study.Health science reports · 2025Article
- Drug Resistance Mutations (DRMs) for Long-Acting Injectable Cabotegravir and Rilpivirine (CAB/RPV LAI) in the HIV-1 Subtype A6 Epidemic in Poland.Microorganisms · 2025Article
- Behind Prep Decisions: Understanding User Patterns and Discontinuation Factors in Real-World.AIDS and behavior · 2024Article
- A Review of FDA-Approved Anti-HIV-1 Drugs, Anti-Gag Compounds, and Potential Strategies for HIV-1 Eradication.International journal of molecular sciences · 2024Review
- Article
- HIV and Drug-Resistant Subtypes.Microorganisms · 2023Review
- Current drugs for HIV-1: from challenges to potential in HIV/AIDS.Frontiers in pharmacology · 2023Review
- Effect of the array of amines on the transfection efficiency of cationic peptidomimetic lipid molecules into neural cells.RSC advances · 2022Article
- Antiretroviral Therapy-Induced Dysregulation of Gene Expression and Lipid Metabolism in HIV+ Patients: Beneficial Role of Antioxidant Phytochemicals.International journal of molecular sciences · 2022Review
- Machine learning approaches for drug combination therapies.Briefings in bioinformatics · 2021Review
- Testicular disposition of clofarabine in rats is dependent on equilibrative nucleoside transporters.Pharmacology research & perspectives · 2021Article
- Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs.International journal of biological macromolecules · 2021Review
- HBV/HIV Coinfection: Impact on the Development and Clinical Treatment of Liver Diseases.Frontiers in medicine · 2021Review
- An Update on Antiretroviral Therapy.Advances in experimental medicine and biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The oral once-daily, fixed-dose single-tablet regimen (STR) of dolutegravir/lamivudine (Dovato
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.